In this light, it is interesting to recall that pyridostigmine, an anticholinesterase inhibitor, capable of reducing hypothalamic somatostatin tone, was reported to improve exercise-induced GH release in patients suffering from FM, thus suggesting the existence of a somatostatin hypertone, a condition that has been supposed to occur also in obesity [18]. The gene discussed is GH1; the disease is obesity due to melanocortin 4 receptor deficiency.